CRISPR Therapeutics AG (CRSP)
Market Cap | 5.12B |
Revenue (ttm) | 38.05M |
Net Income (ttm) | -467.80M |
Shares Out | 90.95M |
EPS (ttm) | -5.44 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 2,000,443 |
Open | 56.10 |
Previous Close | 55.89 |
Day's Range | 55.10 - 56.49 |
52-Week Range | 30.04 - 71.13 |
Beta | 1.81 |
Analysts | Buy |
Price Target | 72.27 (+28.46%) |
Earnings Date | Nov 4, 2025 |
About CRSP
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company’s CRISPR/Cas9 is a revolutionary technology for gene editing which is the process of precisely altering specific sequences of genomic DNA. It has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, CAR T cell therapies, in vivo, and type 1 diabetes, a... [Read more]
Financial Performance
In 2024, CRISPR Therapeutics AG's revenue was $37.31 million, a decrease of -89.95% compared to the previous year's $371.21 million. Losses were -$366.25 million, 138.4% more than in 2023.
Financial StatementsAnalyst Summary
According to 16 analysts, the average rating for CRSP stock is "Buy." The 12-month stock price target is $72.27, which is an increase of 28.46% from the latest price.
News

CRISPR Therapeutics to Present Late-Breaking Data at the American Heart Association (AHA) Scientific Sessions 2025
ZUG, Switzerland and BOSTON, Sept. 09, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious dise...

Biotech Sector Shows No Signs of Slowing. 3 Stocks That Make the Grade.
Last week, the SPDR S&P Biotech ETF surged 6%.

CRISPR Therapeutics AG (CRSP) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
CRISPR Therapeutics AG (NASDAQ:CRSP) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 8:30 AM EDT Company Participants Samarth Kulkarni - CEO & Chairman Conference Call Parti...

CRISPR Therapeutics AG (CRSP) Presents at H.C. Wainwright 27th Annual Global Investment Conference Transcript
CRISPR Therapeutics AG (NASDAQ:CRSP) H.C. Wainwright 27th Annual Global Investment Conference September 8, 2025 4:30 PM EDT Company Participants Raju Prasad - Chief Financial Officer Conference Call ...

Crispr Therapeutics: A Winning Lottery Ticket Doesn't Replace Grand Strategy
CRISPR stock is a bold investment in the future. Beyond the valuation, thematically and based on current market dynamics, I consider this a venture-style winner. Just because CRISPR stock may be a win...

CRISPR Therapeutics to Participate in Upcoming Investor Conferences
ZUG, Switzerland and BOSTON, Sept. 02, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious dise...

Crispr Therapeutics: A Speculative Buy With Promising Potential Ahead
Despite pipeline setbacks and slow CASGEVY rollout, future revenue acceleration and expansion into cardiovascular and autoimmune diseases offer significant long-term growth opportunities. The company ...

Cathie Wood's Top 10 Stock Picks: Unpacking Ark Funds Innovation Picks For The Next Decade
Ark Invest CEO Cathie Wood is known for her stock picks over the last decade, handpicking many of the growth stocks that find their way into the company's ETFs.

Upgrading Crispr Therapeutics To Hold Ahead Of A Catalyst-Rich 2H 2025
CRISPR Therapeutics' recent in vivo CTX310 data validates its technology, marking a fundamental shift and supporting a rating upgrade from Sell to Hold. CASGEVY sales are growing but remain unprofitab...

CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results
-CASGEVY ® momentum building; >75 authorized treatment centers (ATCs) activated globally, achieving the target goal and ~115 patients have had cells collected across all regions; positioning the progr...

Crispr Therapeutics: Shares Are Soaring - This Could Be The Start Of Something Big
Crispr Therapeutics AG stock has surged nearly 90% since my Buy call in early May, reaching its highest value since February 2024. The rally builds on the historic approval of Casgevy, a gene editing ...
The Big 3: ASML, GOOGL, CRSP
ASML Holding (ASML) is "the machine that makes the machine," says Joe Tigay, referring to its importance in Nvidia's (NVDA) chipmaking process. While the stock closed the gap from April lows, he says ...

Crispr Therapeutics' Bright Future Is Coming Into Focus (Rating Upgrade)
Curing disease, as opposed to just masking symptoms, is a big deal. CRISPR Therapeutics aims to cure by editing problem genes. So CRSP is the future of medicine! This approach can be too futuristic fo...

CRISPR Therapeutics Reports Positive Additional Phase 1 Data for CTX310™ Targeting ANGPTL3 and Provides Update on In Vivo Cardiovascular Pipeline
-New Phase 1 clinical data for CTX310™ continues to demonstrate dose-dependent reductions in triglycerides (TG) and low-density lipoprotein (LDL), with peak reduction of up to 82% in TG and up to 86% ...
The Big 3: CRSP, OKLO, GME
Mike Shorr (@ProsperTradingAcademy) looks to manage risk levels in his 3 example options trades. For Crispr Therapeutics (CRSP), he's looking at low-implied volatility in the gene-editing biotech comp...

Crispr Therapeutics: Betting On A One-Shot Future
Crispr Therapeutics AG is transitioning to a commercial company, with CASGEVY's rollout and a robust pipeline in cardiovascular, autoimmune, and oncology driving long-term potential. The cardiovascula...

CRISPR Therapeutics AG (CRSP) Goldman Sachs 46th Annual Global Healthcare Conference (Transcript)
CRISPR Therapeutics AG (NASDAQ:CRSP) Goldman Sachs 46th Annual Global Healthcare Conference June 9, 2025 3:20 PM ET Company Participants Samarth Kulkarni - CEO & Chairman Conference Call Participants...

CRISPR Therapeutics AG (CRSP) William Blair's 45th Annual Growth Stock Conference (Transcript)
CRISPR Therapeutics AG (NASDAQ:CRSP) William Blair's 45th Annual Growth Stock Conference June 3, 2025 12:20 PM ET Company Participants Raju Prasad - Chief Financial Officer Conference Call Participan...

Crispr Therapeutics: Complex Casgevy Launch, But Broader Gene-Editing Potential Still Shines
CRSP's main value driver is Casgevy, which was approved for sickle cell disease and β-thalassemia. It's a one-time ex vivo CRISPR/Cas9 stem‐cell therapy. Unfortunately, Casgevy's rollout has been slow...

CRISPR Therapeutics Struggles Under Slow Adoption And Regulatory Uncertainty (Downgrade)
CRISPR Therapeutics' stock is down 20% since March, with ongoing high cash burn despite a robust $1.86 billion cash position. Casgevy's commercialization is slow, with over 65 treatment centers active...

Crispr Therapeutics Q1 Earnings Analysis: Ignore The Gloom, Stay The Course
CRISPR Therapeutics AG reported a Q1 net loss of $136m, but maintains a strong cash position with $1.86bn in cash and marketable securities. Casgevy, a gene therapy for Sickle Cell Disease, has seen s...

CRISPR Therapeutics' Data Shows Promise, But RFK Jr. Appointee Could Be Negative: Analyst
CRISPR Therapeutics AG CRSP reported new topline study results on Wednesday to establish risk factors for atherosclerotic heart disease.

These Analysts Slash Their Forecasts On CRISPR Therapeutics Following Q1 Results
CRISPR Therapeutics AG CRSP posted a loss for the first quarter on Tuesday.

CRISPR Therapeutics Provides First Quarter 2025 Financial Results and Announces Positive Top-Line Data from Phase 1 Clinical Trial of CTX310™ Targeting ANGPTL3
-Initial CTX310™ Phase 1 clinical data demonstrates dose-dependent decreases in triglycerides (TG) and low-density lipoprotein (LDL), with peak reduction of up to 82% in TG and up to 81% in LDL, with ...

CRISPR Therapeutics And Intellia Therapeutics: Balancing Market Uncertainty Against Pipeline Catalysts
Gene therapy stocks like CRISPR Therapeutics and Intellia Therapeutics are facing significant volatility in 2025, influenced by market instability and regulatory uncertainties. CRSP is better position...